{"id":"NCT00993317","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis","officialTitle":"A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 24-week Study to Assess the Efficacy and Safety of Certolizumab Pegol as Additional Medication to MTX in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2011-08","completion":"2011-08","firstPosted":"2009-10-12","resultsPosted":"2012-09-27","lastUpdate":"2012-09-27"},"enrollment":127,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Placebo of CDP870","otherNames":[]},{"type":"DRUG","name":"CDP870 200mg","otherNames":["CIMZIA"]},{"type":"DRUG","name":"Methotrexate","otherNames":[]}],"arms":[{"label":"Placebo of CDP870+MTX","type":"PLACEBO_COMPARATOR"},{"label":"CDP870 200mg+MTX","type":"EXPERIMENTAL"}],"summary":"The objective of this trial is to compare the efficacy of Certolizumab (CZP) (CDP870) in combination with Methotrexate (MTX) to MTX alone in the treatment of signs and symptoms in patients with active rheumatoid arthritis (RA) who are incomplete responders to MTX.","primaryOutcome":{"measure":"ACR20 Responses at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"Placebo of CDP870+MTX","deltaMin":11,"sd":null},{"arm":"CDP870 200mg+MTX","deltaMin":54,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":15,"countries":["South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":42},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Abdominal pain upper","Cough","Dyspepsia"]}}